Obesity‑drug access limits

Eli Lilly says the ceiling for weight-loss drugs may be lower than Wall Street’s patient counts suggest: about half of eligible people, not all of them. (aol.com) At a conference on April 17, Lilly Chief Executive David Ricks said healthcare-system complexity and financial limits could keep obesity drugs from reaching more than roughly 50% of overweight and obese people who could benefit. Reuters reported the comment from Washington on April 17. (aol.com) The timing matters because Lilly just launched Foundayo, its once-daily obesity pill, after the Food and Drug Administration approved it on April 1 for adults with obesity or overweight plus weight-related medical problems. Lilly said shipping began April 6 through LillyDirect, with prices starting at $25 a month for some commercially insured patients and $149 for self-pay buyers. (investor.lilly.com) (finance.yahoo.com) Early prescription data show a slower start for Lilly’s pill than for Novo Nordisk’s oral Wegovy. Pharm Exec reported Foundayo drew 1,390 prescriptions in its first days on the market, while Reuters reported oral Wegovy reached 3,071 U.S. retail prescriptions in its first four days after its January 5 launch. (pharmexec.com) (money.usnews.com) Those first-week numbers do not measure the full market by themselves. Reuters said the Wegovy figure covered retail pharmacy prescriptions and excluded fills through Novo Nordisk’s NovoCare Pharmacy, which Barclays analysts said means the true total was higher. (money.usnews.com) The bigger constraint is not demand alone. In the United States, 72.4% of adults age 20 and older were overweight, including obesity, in August 2021 through August 2023, and 40.3% had obesity, according to the Centers for Disease Control and Prevention. (cdc.gov) These drugs work by copying a gut hormone signal that helps control appetite and blood sugar, which is why they moved from diabetes treatment into obesity care. The World Health Organization says GLP-1 therapies can reduce hunger, slow stomach emptying, and in some cases lower risks tied to heart, kidney, and liver disease. (who.int) But insurance coverage still sets the practical market size. Medicare’s long-running exclusion of drugs used for weight loss was not broadly reversed for 2026, even after a 2024 proposal to expand coverage, though the Centers for Medicare & Medicaid Services announced a separate voluntary model on December 23, 2025, to let Medicare Part D plans and state Medicaid agencies cover some GLP-1 medicines while trying to control costs. (kff.org) (cms.gov) Pills could still widen use if patients and doctors prefer them to weekly injections, but the launch data suggest format alone does not erase price and reimbursement barriers. Ricks’ 50% estimate puts a hard number on that limit as Lilly and Novo Nordisk race to turn huge theoretical demand into paid prescriptions. (cnbc.com) (aol.com)